R. Karapetian

发表

Nuclear Oncoprotein Prothymosin α Is a Partner of Keap1: Implications for Expression of Oxidative Stress-Protecting Genes

E. Wanker, S. Melnikov, A. Evstafieva, 2005, Molecular and Cellular Biology.

Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir.

E. Govorkova, Jeremy C. Jones, V. Aladinskiy, 2020, The Journal of antimicrobial chemotherapy.

Divalent metal cation binding properties of human prothymosin alpha.

I. Lyakhov, A. Evstafieva, R. Karapetian, 2000, European journal of biochemistry.

Novel water-soluble lignin derivative BP-Cx-1: identification of components and screening of potential targets in silico and in vitro

V. Anisimov, D. Osolodkin, A. Zherebker, 2018, Oncotarget.

Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.

Y. Ivanenkov, I. Okun, R. Karapetian, 2008, Bioorganic & medicinal chemistry letters.

Aprotinin ‐ a new multi-target drug candidate or "magic shotgun" for the therapy of COVID‐19

S. Poyarkov, A. Ivashchenko, R. Karapetian, 2020 .

Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16

R. Karapetian, I. N. Tyurenkov, E. Morkovin, 2018, Front. Endocrinol..

Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study.

O. Bukhanovskaya, A. Ivashchenko, R. Karapetian, 2021, Journal of psychiatric research.

Sensing prothymosin alpha origin, mutations and conformation with monoclonal antibodies.

A. Evstafieva, R. Karapetian, Y. Rubtsov, 2002, Journal of immunological methods.

Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients

N. Savchuk, S. Poyarkov, A. Ivashchenko, 2021, Viruses.

Genes Expression of Oxidative Stress-Protecting Partner of Keap 1 : Implications for Is a α Nuclear Oncoprotein Prothymosin

E. Wanker, S. Melnikov, A. Evstafieva, 2005 .

The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2

Y. Ivanenkov, B. Zagribelnyy, A. Ivashchenko, 2022, Molecules.

Aprotinin is a potent multi-target drug for the combination therapy of moderate COVID-19 cases

N. Savchuk, S. Poyarkov, A. Ivashchenko, 2020 .

Aprotinin - a New Drug Candidate for The Prevention of SARS-CoV-2 (COVID-19)

A. Tomilov, S. Poyarkov, A. Ivashchenko, 2020 .

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

N. Savchuk, A. Ivashchenko, R. Karapetian, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.

Y. Ivanenkov, M. Veselov, N. Shevkun, 2015, European journal of medicinal chemistry.

Discovery and SAR exploration of N-aryl-N-(3-aryl-1,2,4-oxadiazol-5-yl)amines as potential therapeutic agents for prostate cancer

R. Karapetian, Y. Lavrovsky, M. Krasavin, 2010, Chemistry Central journal.

Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.

I. Konstantinov, R. Karapetian, E. Hamel, 2014, Bioorganic & medicinal chemistry letters.

Discovery and Potency Optimization of 2‐Amino‐5‐arylmethyl‐1,3‐thiazole Derivatives as Potential Therapeutic Agents for Prostate Cancer

I. Konstantinov, R. Karapetian, Y. Lavrovsky, 2009, Archiv der Pharmazie.

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

A. Ivashchenko, R. Karapetian, I. Gordeev, 2020 .

Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19

N. Savchuk, A. Ivashchenko, R. Karapetian, 2020, medRxiv.

New Functions of a Well-Known Protein: Prothymosin α Is Involved in Protecting Cells from Apoptosis and Oxidative Stress

Grigory S. Filonov, S. Melnikov, A. Evstafieva, 2005, Molecular Biology.

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.

Y. Ivanenkov, V. Aladinskiy, B. Zagribelnyy, 2020, Bioorganic & medicinal chemistry.

Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).

Y. Ivanenkov, M. Veselov, V. Bichko, 2014, Journal of medicinal chemistry.

Novel oral anti-influenza drug candidate AV5080.

Y. Ivanenkov, M. Veselov, V. Bichko, 2014, The Journal of antimicrobial chemotherapy.

Novel oral anti-influenza prodrug candidate AV5075S.

Y. Ivanenkov, M. Veselov, V. Bichko, 2014, Journal of Antimicrobial Chemotherapy.

Non-rigid Diarylmethyl Analogs of Baloxavir as CAP-Dependent Endonuclease Inhibitors of Influenza Viruses.

E. Govorkova, Jeremy C. Jones, V. Aladinskiy, 2020, Journal of medicinal chemistry.

Discovery and Potency Optimization of 2‐Amino‐5‐arylmethyl‐1,3‐thiazole Derivatives as Potential Therapeutic Agents for Prostate Cancer

I. Konstantinov, R. Karapetian, Y. Lavrovsky, 2009, Archiv der Pharmazie.

Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs).

Y. Ivanenkov, V. Aladinskiy, A. Ivashchenko, 2020, European journal of medicinal chemistry.

Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment

N. Shevkun, R. Karapetian, A. Ivachtchenko, 2014, Journal of Cancer.